Barely Significant
← all excerpts

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.

JAMA Dermatol · 2024 · PMC11255973 · PMID 39018038

Europe PMCDOI
1
hedged sentence
0.0300
closest p · 0.6× alpha
0.0300
boldest claim

The sentences

nominally significantP = .03actually significant
The treatment effect for 360 mg, every 2 weeks vs placebo was nominally significant (−16.3%; nominal P = .03); however, significance could not be claimed because the hierarchical testing sequence was interrupted.

also in 1,047 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.